P53 gene: Mutation and immunohistochemical analysis in patients with invasive ductal carcinoma of breast

被引:0
作者
机构
[1] Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi
[2] Department of Biochemistry, Banaras Hindu University, Varanasi
[3] Cancer Research Institute, N. E. Railways, Lehertara, Varanasi
[4] Department of Pathology, Cancer Research Institute, N. E. Railways, Lehertara, Varanasi
[5] Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi
来源
Singh, S. | 1600年 / Science Publications卷 / 09期
关键词
Breast cancer; ER; HER2; p53; PR;
D O I
10.3844/ajbbsp.2013.395.403
中图分类号
学科分类号
摘要
The p53 tumor suppressor gene is the most commonly mutated gene in cancer. In breast cancer, the presence of p53 gene alterations has been associated with worse prognosis. This study was attempted to associate p53 gene mutations with its protein expression in North Eastern Indian population. We used single-stranded conformation polymorphism to screen samples for mutations in five conserved regions, exons 4, 5, 6, 7 and 8, of the p53 gene. Mutations were confirmed by direct DNA sequencing. Samples were also analyzed for expression of p53 immunohistochemically. We found two critical mutations in the exon 4. A well known missense mutation at codon 72 (pro to arg) with a frequency of 47% was found which was significantly correlated with the immunohistochemical analysis of p53 protein in such patients. A novel nonsense mutation at codon 107 which leads to stop codon was also found. Although the occurrence of this mutation was very less, we did not find expression of p53 protein immunohistochemicaly. We support that mutation in p53 gene can be exploited as a prognostic marker for the early diagnosis of breast cancer, although more clinical and epidemiological data is required to establish this claim. © 2013 Science Publication.
引用
收藏
页码:395 / 403
页数:8
相关论文
共 41 条
  • [31] Nandakumar A., Anantha N., Venugopal T.C., Sankaranarayanan R., Thimmasetty K., Et al., Survival in breast cancer: A population-based study in Bangalore, India, Int J., Cancer, 60, pp. 593-596, (1995)
  • [32] Nayak B.K., Das B.R., Differential binding of nuclear proteins to the TP53 gene promoter in male breast tumour, Eur. J. Cancer, 33, pp. 1484-1487, (1997)
  • [33] Nayak B.K., Das B.R., Differential binding of NF1 transcription factor to P53 gene promoter and its depletion in human breast tumours, Mol. Biol. Rep, 26, pp. 223-230, (1999)
  • [34] Nayak B.K., Das B.R., Mutation and methylation status of p53 gene promoter in human breast tumours, Tumour Biol, 20, pp. 341-346, (1999)
  • [35] Nayak B.K., Baral R.N., Das B.R., p53 gene mutation in relation to p53 protein accumulation in male and female breast cancer, Neoplasma, 43, pp. 305-310, (1996)
  • [36] Nayak B.K., Patnaik S., Das B.R., Rearrangement of the p53 gene in human breast tumours, Biochem. Biophys. Res. Commun, 245, pp. 388-391, (1998)
  • [37] Papadakis E.N., Dokianakis D.N., Spandidos D.A., P53 codon 72 polymorphism as a risk factor in the development of breast cancer, Mol. Cell Biol. Res. Commun, 3, pp. 389-392, (2000)
  • [38] Peng Y., Chen L., Li C., Lu W., Chen J., Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization, J. Biol. Chem, 276, pp. 40583-40589, (2001)
  • [39] Sambrook J., Russell D.W., Molecular Cloning: A Laboratory Manual. 3rd Edn, (2001)
  • [40] Sharma R.G., Ajmera R., Saxena O., Cancer profile in eastern Rajasthan, Indian J. Cancer, 31, pp. 160-173, (1994)